Home » Infectious Disease » MERINO Trial: Piperacillin-Tazobactam vs Meropenem in ESBL infections

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

MERINO Trial of using pip tazo for patients with ESBL infection

MERINO Trial: 2018, Pip-Tazo vs Meropenem in patients with E-coli or Klebsiella infections,  JAMA

Earlier cohort studies yielded conflicting results when it comes to treating ceftriaxone-resistant E-coli and Klebsiella infections. Some studies reported noninferiority of piperacillin-tazobactam when compared to meropenem while others reported almost doubling of mortality.

In the MERINO trial, the patients were randomized to assess for non-inferiority of pip-tazo IV therapy versus IV meropenem. The results showed 12.3% 30-day mortality in the pip-tazo group compared to 3.7% with meropenem. Therefore, the study concluded that for E-coli and Klebsiella bloodstream infections, pip-tazo antibiotic is inferior to meropenem in terms of 30 days mortality.

MERINO Trial: Piperacillin-Tazobactam vs Meropenem in ESBL infections